besremi
aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulanti, - besremi huwa indikat bħala monoterapija fl-adulti għat-trattament ta ' poliċitemija vera mingħajr sintomatika splenomegalija.
balaxur
merz pharmaceuticals gmbh - memantine hydrochloride, donepezil hydrochloride - marda ta 'alzheimer
thiotepa riemser
esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - aġenti antineoplastiċi - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
axura
merz pharmaceuticals gmbh - memantina idrokloridu - marda ta 'alzheimer - mediċini oħra kontra d-demenzja - trattament ta 'pazjenti b'mard ta' alzheimer moderat għal sever.
prialt
esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analġeżiċi - ziconotide huwa indikat għall-kura ta 'uġigħ sever u kroniku f'pazjenti li jeħtieġu analġeżija intrateġika (it).
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - imblokk neuromuskolari - il-prodotti terapewtiċi l-oħra kollha - it-treġġigħ lura ta 'imblokk newromuskolari kkawżat minn rocuronium jew vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
vantobra (previously tobramycin pari)
pari pharma gmbh - tobramycin - respiratory tract infections; cystic fibrosis - antibatteriċi għal użu sistemiku, - vantobra huwa indikat għall-ġestjoni ta 'infezzjoni pulmonari minħabba pseudomonas aeruginosa fit-pazjenti ta' bejn 6 snin u akbar b'fibrożi ċistika (cf). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.
nerventra
teva pharma gmbh - laquinimod - sklerosi multipla - il-kura tal-isklerożi multipla.
clopidogrel tad
tad pharma gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - aġenti antitrombotiċi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
duloxetine boehringer ingelheim
boehringer ingelheim international gmbh - duloxetine - neuropatiji dijabetiċi - psychoanaleptics, - trattament ta 'uġigħ newropatiku periferali dijabetiku fl-adulti.